Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

CARdiomyopathy in type 2 DIAbetes mellitus

Project description

Big data and biobanks support improved diagnosis and treatment for heart disease in diabetics

The prevalence of type 2 diabetes has reached a pandemic scale with patients at an elevated risk for developing cardiomyopathy, a heart muscle disease that makes it difficult for the heart to pump blood, and heart failure is a leading cause of death. While diabetic cardiomyopathy (DCM) has been recognised as a distinct clinical condition, it is not certain if DCM does in fact have different development and disease progression compared to conventional cardiomyopathy. The CARDIATEAM initiative intends to answer this question by comparing diabetes and heart failure patients and healthy controls. Finding biomarkers of DCM while simultaneously developing big-data processing techniques to identify risk groups based on phenotypic differences should foster early diagnosis and treatment for better outcomes.

Objective

A rapidly evolving epidemic in Type 2 Diabetes (T2DM) is afflicting all ages, sexes and socioeconomic classes which includes serious comorbidities such as heart diseases. While ischaemic heart disease represents the major cause of death of T2DM patients, heart failure (80% of Heart Failure with preserved Ejection Fraction) is the second most common cardiovascular disease in T2DM patients. The aim of CARDIATEAM is to determine whether T2DM represents a central mechanism contributing to the pathogenesis and progression of a specific cardiomyopathy, called “diabetic cardiomyopathy” (DCM), assessing whether DCM is unique and distinct from the other forms of heart failure.
To achieve this aim CARDIATEAM will build up a deeply phenotyped cohort, including an innovative imaging protocol, based on privileged access within the CARDIATEAM to already existing highly pertinent cohorts of diabetes and heart failure patients and control groups. Central biobanking of the cohort samples will allow detailed omics analysis that will feed together with the phenotype and imaging data into the central CARDIATEAM database. The data gathered will enable unsupervised machine-learning for clustering this heterogeneous population on phenotypic differences beyond diabetes. State-of-the-art big-data processing techniques and disease modeling will allow for controlling for common confounders such as BMI, smoking, age and blood pressure and will finally lead to the identification of new imaging and molecular biomarkers as well as understanding the taxonomy of the development and progression of DCM. Tailored preclinical models will be developed to explore the identified pathways revealing new therapeutic targets.
The results of CARDIATEAM will be able to impact clinical care with the stratification of patients into risk groups of developing DCM, earlier diagnosis of DCM and an improvement of therapy thanks to better assessment of underlying pathophysiology and identification of new biomarkers.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

RIA - Research and Innovation action

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) H2020-JTI-IMI2-2017-13-two-stage

See all projects funded under this call

Coordinator

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 1 053 229,18
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 2 923 240,30

Participants (31)

My booklet 0 0